Amyloid-Beta Immunotherapies for Alzheimer's Disease: Current Progress

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Alzheimer's Disease (AD) is a leading cause of dementia globally, characterized by amyloid-beta (Aβ) accumulation.
• Aβ plaque buildup disrupts neuronal integrity and initiates neurodegenerative processes.
• Immunotherapy targeting Aβ is a key strategy for disease modification in AD.

Purpose of the Study:

• To comprehensively review active and passive immunotherapies targeting Aβ that have entered clinical trials.
• To analyze the evolution, challenges, and future directions of Aβ-directed treatments for Alzheimer's Disease.

Main Methods:

• Review of clinical trial data for Aβ-targeted immunotherapies (active and passive).
• Analysis of safety, efficacy, and regulatory advancements.
• Evaluation of challenges including patient selection, monitoring, and long-term outcomes.

Main Results:

• Early Aβ vaccines and monoclonal antibodies faced safety and efficacy challenges.
• Recent approvals (Aducanumab, Lecanemab, Donanemab) demonstrate Aβ reduction and cognitive slowing.
• Despite progress, modest clinical benefits and uncertainties in long-term modification persist.

Conclusions:

• Aβ-targeted immunotherapies have evolved significantly, offering new therapeutic avenues for AD.
• Ongoing challenges include managing adverse events like ARIA and ensuring equitable global access.
• Further research is crucial for developing effective, long-term disease-modifying therapies for Alzheimer's Disease.